RedHill Biopharma (RDHL) Equity Average: 2015-2024
Historic Equity Average for RedHill Biopharma (RDHL) over the last 10 years, with Dec 2024 value amounting to -$1.3 million.
- RedHill Biopharma's Equity Average fell 3.63% to -$211.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$211.4 million, marking a year-over-year decrease of 3.63%. This contributed to the annual value of -$1.3 million for FY2024, which is 94.36% up from last year.
- RedHill Biopharma's Equity Average amounted to -$1.3 million in FY2024, which was up 94.36% from -$23.2 million recorded in FY2023.
- In the past 5 years, RedHill Biopharma's Equity Average registered a high of $36.9 million during FY2020, and its lowest value of -$23.2 million during FY2023.
- Moreover, its 3-year median value for Equity Average was -$19.8 million (2022), whereas its average is -$14.7 million.
- As far as peak fluctuations go, RedHill Biopharma's Equity Average slumped by 273.82% in 2022, and later skyrocketed by 94.36% in 2024.
- Yearly analysis of 5 years shows RedHill Biopharma's Equity Average stood at $36.9 million in 2020, then crashed by 69.22% to $11.4 million in 2021, then tumbled by 273.82% to -$19.8 million in 2022, then dropped by 17.22% to -$23.2 million in 2023, then soared by 94.36% to -$1.3 million in 2024.